Determination That ANSAID (Flurbiprofen) Tablets, 50 Milligrams and 100 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
FDA determined that ANSAID (flurbiprofen) tablets, 50 mg and 100 mg, were not withdrawn from sale for reasons of safety or effectiveness, which may affect the regulatory status of these products.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 14, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Manufacturers, distributors, and marketers of flurbiprofen tablets, particularly those with approved NDAs or ANDAs for these products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline stated.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA officially determined that ANSAID (flurbiprofen) tablets were not withdrawn from sale for safety or effectiveness reasons, which may clarify the regulatory status and potentially affect market exclusivity or approval pathways.
Who it affects
Manufacturers, distributors, and marketers of flurbiprofen tablets, particularly those with approved NDAs or ANDAs for these products.
What you must do
Review the determination and assess any impact on your product's regulatory status, marketing, or future applications.
Deadline
No specific deadline stated.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- FDA Issues Final Rule Clarifying Evidence of Off-Lab... - Dechert
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
- International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
- Determination That CABAZITAXEL (Cabazitaxel) Solution (Injection), 60 Milligrams/6 Milliliters (10 Milligrams/Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- PA HB 2749: An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for drug overdose medication.